S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
ASX:IVX

Invion Limited (IVX.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.01
MA: A$0.01
A$0.01
52-Week Range N/A
Volume471,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.

MarketRank

Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9081 6005
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.48 million
Book ValueA$0.00 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive IVX News and Ratings via Email

Sign-up to receive the latest news and ratings for IVX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Invion Limited (IVX.AX) (ASX:IVX) Frequently Asked Questions

What stocks does MarketBeat like better than Invion Limited (IVX.AX)?

Wall Street analysts have given Invion Limited (IVX.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Invion Limited (IVX.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Invion Limited (IVX.AX)'s key competitors?

What other stocks do shareholders of Invion Limited (IVX.AX) own?

Who are Invion Limited (IVX.AX)'s key executives?

Invion Limited (IVX.AX)'s management team includes the following people:
  • Mr. Thian Chew, Interim CEO & Exec. Chairman
  • Ms. Melanie Jaye Leydin C.A., B.Bus, CA, CFO & Company Sec. (Age 47)
  • Dr. Dean Naylor, Head of Intellectual Property Devel.

What is Invion Limited (IVX.AX)'s stock symbol?

Invion Limited (IVX.AX) trades on the ASX under the ticker symbol "IVX."

How big of a company is Invion Limited (IVX.AX)?

Invion Limited (IVX.AX) has a market capitalization of $0.00 and generates $3.48 million in revenue each year.

What is Invion Limited (IVX.AX)'s official website?

The official website for Invion Limited (IVX.AX) is www.inviongroup.com.

How can I contact Invion Limited (IVX.AX)?

The company can be reached via phone at 61 3 9081 6005.

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.